US FDA's Assessment of the Benefit-risk of Cefiderocol for its Initial Complicated Urinary Tract Infection Indication.

ABSTRACT:

SUBMITTER: Echols RM 

PROVIDER: S-EPMC8366820 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature